Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.20.2
Inventory
9 Months Ended
Sep. 30, 2020
Inventory  
Inventory

4.

Inventory

Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard® Nerve Protector, Axoguard® Nerve Cap, Avive® Soft Tissue Membrane, Acroval® Neurosensory and Motor Testing System, Axotouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:

    

September 30,

    

December 31,

    

2020

2019

Finished goods

$

8,339

$

10,403

Work in process

 

798

 

730

Raw materials

2,792

 

2,728

Inventories

$

11,929

$

13,861

The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes-down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage.  For the nine months ended September 30, 2020 and 2019, the Company had adjustments to the provision for inventory write downs of $2,108 and ($44) respectively.